Thailand PGT CMS

标签： pgt-a

  • Day-Five, Day-Six and Day-Seven Blastocyst Labels: What the Numbers Mean

    If your embryo report lists something like “day-5 blastocyst” or “day-6 blastocyst,” the number is a timing note. It records the day, counted from insemination or fertilisation, on which the laboratory observed that embryo reach the blastocyst stage. It is not the day of your transfer, it is not a grade, and it is not a genetic test result.

    That single sentence answers most of the confusion. The rest of this guide explains why the timing differs between embryos, how to read the label next to the other information in your report, and what is worth confirming with the treating team.

    What the laboratory is actually recording

    After fertilisation, an embryo divides through several stages. At the blastocyst stage it has formed a fluid-filled cavity and two distinguishable cell populations: the inner cell mass, which will form the fetus, and the trophectoderm, which will form the placenta. Embryos do not all arrive at this point on the same day.

    In a typical reporting convention, day 0 is the day of insemination or fertilisation. An embryo first seen as a blastocyst on the fifth day after that is labelled day 5; one that gets there on the sixth or seventh day is labelled day 6 or day 7. The label therefore describes developmental pace in the laboratory’s culture, observed on a particular day.

    Two practical points follow. First, laboratories differ in how they count days and when they inspect embryos, so the same embryo could in principle be described slightly differently elsewhere. Second, the label is a snapshot of one observation, not a running commentary on everything that happened in the incubator.

    Why some embryos reach the blastocyst stage later

    Development is a biological process with natural variation. Some embryos simply take longer to form a cavity and organise their cells. The day label captures that difference in pace; it does not, by itself, explain the cause.

    This matters because patients often read a later day number as a verdict. It is better understood as one piece of laboratory information among several. How much weight a clinic gives to developmental timing, and how it combines that with morphology grading, is a matter of that clinic’s own criteria and experience. Those criteria are not universal, and they are not something a general guide can supply for your specific embryo.

    Reading the label alongside the rest of the report

    A day label rarely appears alone. Most reports also include a morphology grade describing the expansion of the cavity, the inner cell mass and the trophectoderm, and, where testing was performed, a separate genetic result. These are different kinds of information and should not be collapsed into one another.

    Item on the report What it describes What it does not describe
    Day number (5, 6 or 7) When the blastocyst stage was first observed, counted from insemination or fertilisation Quality, genetic status, or the day of transfer
    Morphology grade Appearance of the cavity, inner cell mass and trophectoderm at assessment A guarantee of implantation or a genetic result
    PGT report (if performed) Findings from cells sampled from the embryo A whole-embryo diagnosis or a guarantee of a healthy child

    Keeping these rows separate in your mind is useful when you speak to the clinic, because each one answers a different question. If you are still working out how a genetic result is worded, the guide to reading PGT-A results after IVF walks through the common categories, and PGT-A result categories explained in plain language covers what to ask a clinician to clarify.

    It also helps to know what PGT-A can and cannot do. The HFEA describes PGT-A as assessing chromosome number in cells sampled from an embryo, and notes that testing has limitations and can produce incorrect findings; a result does not guarantee a successful pregnancy or a healthy child. A day label sits outside that discussion entirely — it is a timing observation, not a test.

    What the day label does not mean

    • It is not a quality score. A day-6 blastocyst is not automatically “worse” than a day-5 one, and a day-5 label does not certify a strong embryo.
    • It is not a transfer date. Transfer timing is a separate clinical and logistical decision.
    • It is not a genetic result. PGT findings come from a separate report and a separate laboratory process.
    • It is not a prediction of your individual chance of pregnancy. That depends on many factors your clinician can discuss with you.
    • It is not comparable across clinics without checking. Counting conventions and assessment schedules vary between laboratories.

    Day-7 blastocysts in particular

    Day-7 blastocysts are a recognised but less common category. Because they are less common, clinics differ in whether they continue culturing to day 7 at all, and in their policies on transferring or freezing embryos that reach the blastocyst stage that late. Some laboratories may not routinely culture beyond day 6. This is a service and policy question for the clinic, not something a general article can settle.

    If your report includes a day-7 embryo, the useful next step is to ask the treating team how they view it in your specific situation, including whether it would be considered for transfer, freezing or further testing, and on what basis.

    Questions worth putting to the treating team

    These are clinical and laboratory questions, and the embryology or medical team is the right source for the answers. You can ask them directly, in a consultation or by message through the clinic’s usual channel.

    1. How does this laboratory count days — from insemination, from fertilisation, or from another reference point?
    2. When are embryos assessed, and could an embryo’s label change if it were assessed on a different schedule?
    3. Does the laboratory routinely culture embryos to day 7, and what is its policy on day-7 embryos?
    4. How does the clinic weigh developmental timing against morphology grade when selecting among embryos?
    5. How should I read this day label together with the morphology grade and any PGT report?
    6. What would you want me to understand about this particular embryo’s report?

    If you are also trying to understand the wider sequence — what happens between retrieval and the report landing in your inbox — the overview of what happens between egg retrieval and the embryo report sets out the stages, and how long PGT-A biopsy takes and whether it adds time to a cycle covers the laboratory timeline. For the difference between earlier-stage embryos and blastocysts, see cleavage-stage embryos and blastocysts compared.

    Keeping your own record straight

    Reports arrive at stressful moments, and small details blur. A simple habit helps: note the date you received each report, keep the original document unedited, and write down the day label, morphology grade and any PGT wording exactly as printed rather than paraphrasing from memory. If you are comparing information from more than one clinic, keep each clinic’s documents separate so conventions are not mixed up.

    If you are preparing questions before a consultation, it can help to sort them into three groups: what the report says, what it means for your options, and what happens next. The first group is often answerable from the documents themselves; the second and third belong with the treating clinician.

    Where coordination help fits, and where it does not

    Arranging a remote consultation, gathering records before an appointment, or requesting a copy of a laboratory report after you return home are practical tasks that a coordination service can assist with. Interpreting what a day label means for your embryo, recommending whether to transfer or freeze a particular embryo, and advising on your individual chances are clinical matters for the treating team and, where relevant, a genetic counsellor.

    If you would like help organising your questions and the documents you already hold before approaching a hospital, you can request a case review. The output is a structured question list and a record checklist with unconfirmed items clearly marked — not a medical opinion.

    Frequently asked questions

    Does a day-5 blastocyst have a better chance than a day-6 blastocyst?

    The day number records when the blastocyst stage was first observed, not a quality rating. How much weight a clinic gives to developmental timing, alongside morphology grading and any other information, is a matter of that clinic's own criteria. Your treating clinician is the right person to discuss what the label means for your specific embryo.

    If my embryo is labelled day 6, does that mean it developed too slowly?

    It means the laboratory first observed the blastocyst stage on the sixth day after insemination or fertilisation, which reflects natural variation in developmental pace in culture. Whether that timing matters for your situation depends on the clinic's criteria and the rest of the embryo's report, so it is worth asking the embryology or medical team directly.

  • Why a Euploid PGT-A Result Does Not Guarantee Implantation

    A euploid PGT-A result is reassuring, and it is easy to read it as a promise. It is not one. The result describes the chromosome number seen in a small sample of cells taken from the embryo. It does not confirm that every cell in that embryo is normal, and it says nothing about whether the embryo will continue developing, hatch from its shell, or meet a uterus ready to receive it.

    That is why a euploid result can sit alongside a transfer that does not lead to pregnancy. The gap has two parts: what the test can and cannot see, and everything outside the test that still has to go right. Keeping those two layers separate makes a report easier to interpret and makes a conversation with your clinician more useful.

    What a euploid result actually describes

    PGT-A assesses chromosome number in cells sampled from an embryo. In typical practice the sample comes from the trophectoderm, the outer layer that will form the placenta, not from the inner cell mass that will form the fetus. The lab reports what it found in that sample.

    So a euploid call is best understood as a probability statement about the sampled cells. It means the sample showed the expected number of chromosomes. It is not a whole-embryo diagnosis and not a statement about the future pregnancy. The UK regulator’s patient information makes the same point plainly: testing has limitations, can produce incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child (HFEA: PGT-A).

    This is also why the test is a discussion point rather than an automatic step. Whether PGT-A suits a particular situation depends on history, age, the number of embryos available and what you want the information for. Your treating team can weigh those factors with you.

    Test limits: where a euploid report stops short

    Several limits sit between “the sample looked euploid” and “this embryo is chromosomally normal in every cell.” None of them means the test is useless. They mean the result needs context.

    The sample is not the whole embryo

    A biopsy removes a few cells from one region of the embryo. The rest of the embryo is not tested. A normal-looking sample makes an abnormal whole embryo less likely, but it cannot rule it out. This sampling gap is the core reason a euploid result is probabilistic rather than definitive.

    Mosaicism complicates the picture

    Sometimes a report shows intermediate chromosome copy-number findings rather than a clean euploid or aneuploid call. This is described as mosaicism, and it is inferred from the biopsy sample. Technical factors can contribute to such findings, and a sampled result does not establish the cell composition of the whole embryo. The ASRM committee opinion on mosaic PGT-A results recommends that these findings and their uncertainty be discussed with the treating clinician and a genetic counsellor (ASRM: mosaic PGT-A results). If your report uses mosaic language, that is a conversation to have with your clinician, not a label to interpret alone.

    No-result and inconclusive calls happen

    Not every biopsy yields a clear answer. A sample can fail to amplify, give an unclear signal, or be reported as inconclusive. An inconclusive result is not the same as an abnormal one, and it is not the same as a normal one. Ask what the specific wording on your report means for that embryo and what options exist.

    Platform resolution has boundaries

    Different testing approaches look at chromosomes at different levels of detail. A test designed to count chromosomes may not detect very small changes, and it is not a test for single-gene conditions. PGT-M addresses a known monogenic condition, and PGT-SR addresses chromosomal structural rearrangements; these are different questions from the one PGT-A asks (HFEA: PGT-M and PGT-SR). Knowing which test you had matters when you read the report.

    The biopsy itself carries a small risk

    Embryo biopsy can cause damage and prevent further development. The HFEA notes this as a recognised risk of the procedure (HFEA PGT-A FAQ). It is one more reason the decision to test is individual rather than universal.

    Other factors: what has to go right after the report

    Even setting test limits aside, implantation is not a single event that a chromosome result can control. A euploid embryo still has to complete several biological steps, and the recipient’s body has to be ready at the same time.

    • Embryo developmental potential. An embryo can arrest or fail to hatch after transfer. A chromosome result does not measure these capacities.
    • Endometrial receptivity. The lining has to be receptive at the right moment. Timing and uterine factors sit outside the embryo report.
    • Transfer technique and cycle management. How and when the transfer is performed is part of the clinical picture.
    • Maternal age and general health. These shape the wider context in which a transfer takes place.
    • Clinical history. Previous cycles, diagnoses and prior outcomes inform how your clinician interprets this attempt.

    These factors are why two embryos with the same euploid report can have different outcomes, and why a single failed transfer does not mean the report was wrong. Your clinician can explain which factors are most relevant in your case.

    Per-embryo versus per-transfer: two different questions

    Reports and conversations often blur two questions. The first is about one embryo: does this sample look euploid? The second is about one transfer: will this transfer lead to implantation and an ongoing pregnancy? The first is an input to the second, not the answer to it.

    When you read a report, notice which question it is answering. A euploid call answers the first. It cannot answer the second on its own, because the second depends on the embryo’s full development, the uterine environment and the clinical plan. If someone presents a euploid result as a guarantee, that framing is worth questioning.

    Reading your own report in context

    A useful way to approach a PGT-A report is to separate what the laboratory states from what your clinician interprets.

    What the lab typically reports What it does not establish
    The chromosome finding for the sampled cells The chromosome status of every cell in the embryo
    Whether the call is euploid, aneuploid, mosaic or inconclusive Whether the embryo will implant or develop into a healthy child
    The test performed and its stated scope Single-gene conditions or structural rearrangements unless a different test was used

    For a closer walk through report wording, see how to interpret PGT-A results from a Thai lab and the companion guide on reading a PGT-A report from a Thai laboratory. If your report includes mosaic language, what mosaic PGT-A results mean explains the terminology. For the underlying test purpose, what PGT-A is and why it is used in IVF gives the broader background.

    What to ask your clinician about your individual chances

    You are entitled to ask your treating clinician about your own situation, including what a euploid result does and does not change for you. Questions that tend to produce a useful conversation include:

    • Which test was performed on this embryo, and what does the report’s wording mean in plain language?
    • Does this report include any mosaic or inconclusive findings, and how should those be interpreted?
    • Given my age, history and this cycle, how do you frame the chance of implantation for this transfer?
    • Which factors outside the embryo report are most relevant in my case?
    • If this transfer does not lead to pregnancy, what would you want to review before the next step?

    These are clinical questions, and they belong with your treating team. A coordination service can help you organise records and prepare questions, but it does not diagnose, interpret results for you or prescribe. The clinician who knows your history is the right person to discuss individual chances.

    Practical preparation for an international patient

    If you are travelling to Thailand for treatment, the report conversation is easier when your records are in order before you arrive. A dated list of prior cycles, test reports and current medications helps your clinician see the full picture. If you are comparing clinics, ask how each one handles report discussions and who will explain results to you; a shortlist of providers is a starting point for those questions, not evidence that one clinic will give you a better outcome.

    Remote consultations can be used to go through report wording before travel, and to clarify what will be explained in person. After you return home, a written summary of what was discussed and any outstanding questions is worth requesting so that follow-up does not depend on memory. Coordination can assist with organising records, requesting appointments and passing questions to the hospital; clinical interpretation and medical decisions remain with your treating team.

    The takeaway

    A euploid PGT-A result is genuinely useful information, and it is not a guarantee. It reflects the sampled cells, carries the limits of sampling, mosaicism, inconclusive calls and platform resolution, and it cannot control embryo development, endometrial receptivity, transfer factors or your wider health context. Read the report as one input, ask your clinician what it means for you specifically, and treat any promise of guaranteed implantation with caution.

    Frequently asked questions

    If my embryo is euploid, why did the transfer still fail?

    A euploid result describes the sampled cells, not the whole embryo or the pregnancy. Implantation also depends on embryo development, endometrial receptivity, transfer factors and your clinical history. A failed transfer does not mean the report was wrong; your clinician can review what happened in your case.

    Does a euploid result mean my baby will be healthy?

    No. PGT-A assesses chromosome number in a sample of embryo cells, and the HFEA states that a result does not guarantee a successful pregnancy or a healthy child. Your clinician can explain what the test does and does not cover for your situation.

  • Cleavage-Stage Embryos and Blastocysts: How the Two Stages Differ

    Cleavage-stage embryo and blastocyst are not two kinds of embryo. They are two points on the same developmental path. An embryo that reaches the blastocyst stage has passed through the cleavage stage first. The practical differences are about timing, what the laboratory can see, and what can be done with the embryo at each point.

    This guide explains the sequence, what is observable at each stage, and how those differences shape conversations about PGT and transfer. It does not tell you which stage is right for your treatment; that depends on your own cycle and your treating team’s assessment.

    The short answer

    A cleavage-stage embryo is typically observed around day 2 to day 3 after fertilisation. It has divided into a small number of cells, called blastomeres, and each of those cells can usually be seen individually. There is no fluid-filled cavity.

    A blastocyst is typically observed around day 5 to day 6. The cells have compacted, a fluid-filled cavity has formed, and two distinct populations of cells have appeared: the inner cell mass, which is associated with the future fetus, and the trophectoderm, the outer layer associated with the placenta. These descriptions are general embryology; the exact day an individual embryo reaches a stage varies.

    A day-by-day view of early development

    The timeline below describes the usual sequence after fertilisation. It is a general pattern, not a schedule your embryos must follow.

    • Day 0 to day 1: fertilisation occurs, and the resulting single-cell zygote begins dividing.
    • Day 2 to day 3: the embryo is in the cleavage stage, with a small number of visible cells and no cavity.
    • Day 3 to day 4: the cells begin to compact and adhere more tightly, a transition sometimes called morula formation.
    • Day 5 to day 6: a cavity forms and the embryo becomes a blastocyst, with an inner cell mass and trophectoderm.

    Some embryos develop more slowly or stop developing altogether. A laboratory report that says an embryo had not reached blastocyst by a given day is a description of that embryo at that moment, not a prediction about any future cycle.

    Side-by-side comparison

    Feature Cleavage stage Blastocyst stage
    Typical timing Around day 2 to day 3 after fertilisation Around day 5 to day 6 after fertilisation
    Visible structure Individual cells (blastomeres), no cavity Compacted cells, fluid-filled cavity, inner cell mass and trophectoderm
    Typical reporting language Cell number, symmetry, degree of fragmentation Expansion or hatching description, inner cell mass and trophectoderm grading
    What the laboratory can assess Cell count and appearance of the visible cells Overall structure and the appearance of the two cell populations
    What the laboratory cannot assess Chromosome number or genetic content from appearance alone; how the embryo would have developed later Chromosome number or genetic content from appearance alone; whether an embryo would implant

    Grading systems differ between laboratories, and the same embryo can be described in different words by different teams. If you are comparing reports, it helps to ask each laboratory to explain its own scale rather than assuming the numbers mean the same thing. A separate guide on comparing embryo grading explanations between IVF laboratories sets out what to check.

    Why PGT biopsy is generally done at the blastocyst stage

    PGT-A assesses chromosome number in cells sampled from an embryo. The sample is a biopsy, and the result describes the sampled cells, not the whole embryo with certainty. Testing has limitations and can produce incorrect findings, and a result does not guarantee a successful pregnancy or a healthy child.

    At the blastocyst stage, the trophectoderm is a separate outer layer, so a biopsy can be taken from those cells while the inner cell mass remains. At the cleavage stage, every visible cell is still part of the same undifferentiated group, so removing a cell is a different proposition. This is why trophectoderm biopsy at blastocyst stage is the usual approach in PGT programmes.

    Biopsy is not risk-free. Embryo biopsy can cause damage and prevent further development. How that risk applies in your situation is a question for your treating clinician and embryologist, not something a general article can quantify for you.

    What happens if embryos do not reach blastocyst

    Extended culture to blastocyst means waiting longer before transfer or freezing. Some embryos stop developing during that wait. If none of your embryos reach the blastocyst stage, there may be no trophectoderm sample to test and no blastocyst to transfer or freeze from that cycle. That outcome is a reason for a careful conversation with your clinician about what the laboratory observed and what options exist, not a verdict on future attempts.

    Because extended culture can reduce the number of embryos available for transfer or freezing, clinics sometimes discuss transferring at cleavage stage instead. That trade-off is a clinical decision for your team, based on your history and the laboratory’s observations.

    Vitrification and transfer timing

    Embryos can be vitrified (fast-cooled) at either stage, and the stage at which an embryo is frozen is recorded in the laboratory report. Transfer timing follows from that: a cleavage-stage transfer happens earlier in the cycle than a blastocyst transfer, and a frozen transfer is scheduled separately from the retrieval cycle.

    Whether a fresh or frozen transfer is planned after PGT is a separate decision with its own considerations. A comparison of fresh versus frozen embryo transfer after PGT covers the pathway differences without recommending one for you.

    Questions worth putting to your own embryologist or clinician

    These are clinical questions, and your treating team is the right place to ask them. A short written list helps you get specific answers rather than general ones.

    • At which stage does this laboratory usually report embryos, and what does its grading scale mean?
    • If extended culture is planned, on which day is blastocyst development assessed, and what happens to embryos that have not reached blastocyst by then?
    • If PGT is planned, which cells are sampled, and what does the report describe?
    • If few or no embryos reach blastocyst in a cycle, what will the team review with us afterwards?
    • At which stage would any embryo be frozen, and how does that affect transfer scheduling?

    You can also ask for the laboratory’s written embryo report and for an explanation of any term you do not recognise. Reports are clinical documents; interpretation belongs with your clinician.

    Where coordination help fits

    Understanding the stages is the clinical part. The practical part is making sure questions reach the right person and that records travel with you. A coordination service can help organise your existing records and a dated list of outstanding documents, request an appointment or remote consultation and confirm the format and any fee status, and assist with language and travel planning around confirmed appointments. After you return home, it can help request records and route follow-up questions to the hospital. It does not interpret results, diagnose, prescribe or promise an outcome, and appointment availability always depends on the hospital.

    If you are at the stage of comparing what clinics include in their written quotations, the guide to what to confirm in writing about PGT-A testing cost in Thailand lists the items worth checking. For a broader look at how clinic success-rate claims are presented, see how to read clinic success-rate claims.

    Sources: Embryo biopsy can cause damage and prevent further development. — HFEA PGT-A frequently asked questions (checked 2026-10-15).

    Frequently asked questions

    Does a blastocyst-stage embryo have a better chance than a cleavage-stage embryo?

    That is a clinical question about your own cycle, and the answer depends on the embryos, your history and the laboratory. What can be said generally is that reaching blastocyst is a sign that an embryo has continued developing, but it does not guarantee implantation or a healthy pregnancy. Ask your treating clinician how the stage question applies to your situation.

    Can PGT be done on a cleavage-stage embryo?

    Trophectoderm biopsy at blastocyst stage is the usual approach because the outer cell layer can be sampled separately from the inner cell mass. Whether any alternative is appropriate in your case is a decision for your treating team and the laboratory, and it should be discussed with you directly rather than assumed.

  • PGT-A vs PGT-SR: What Each Test Looks For and Why the Difference Matters

    PGT-A and PGT-SR are both preimplantation genetic tests performed on a small sample of cells taken from an embryo. The similarity ends there. PGT-A asks a broad question about chromosome number across the embryo’s chromosomes. PGT-SR asks a narrow, pre-defined question about chromosomes affected by a structural rearrangement already known to exist in a parent. One is a screening approach; the other is a targeted test built around a specific family finding.

    If a clinic has mentioned “PGT” without saying which one, the first useful step is to establish which test is actually being proposed and why. The two are not interchangeable, and PGT-SR is not a more thorough version of PGT-A.

    The core difference in one sentence each

    • PGT-A looks at chromosome number — aneuploidy — across the embryo’s chromosomes, to identify embryos with an abnormal number of whole chromosomes.
    • PGT-SR is designed for embryos from a parent who carries a known chromosomal structural rearrangement, such as a translocation or inversion, and looks for unbalanced chromosome content arising from that rearrangement.

    The UK regulator’s patient information describes PGT-A as assessing chromosome number in sampled embryo cells, and separately describes PGT-SR as addressing chromosomal structural rearrangements — different questions requiring different test design. That distinction is the heart of the matter.

    Why the indications differ

    PGT-A is typically raised in conversations about age-related risk, a history of recurrent pregnancy loss, or certain male-factor situations, where the concern is a random chromosome-number error in the embryo. PGT-SR enters the conversation through a different door: a karyotype result, or another genetic finding, showing that a parent carries a balanced structural rearrangement.

    A balanced rearrangement can leave a parent healthy while raising the chance that an embryo inherits an unbalanced amount of chromosome material. PGT-SR is built to look for that specific pattern. It is not a general screen for aneuploidy across all chromosomes, and it does not replace PGT-A unless the treating team has designed it to do both.

    Why PGT-SR needs preparation PGT-A does not

    PGT-SR cannot be ordered as a generic add-on. It depends on prior information:

    1. A documented parental karyotype or equivalent finding identifying the rearrangement and the chromosomes involved.
    2. A tailored probe design built around that specific rearrangement, which takes laboratory work before an embryo biopsy can be interpreted.
    3. Genetic counselling to explain inheritance patterns, what the test can and cannot detect, and what the results mean for the family.

    This is why the practical preparation for PGT-SR often starts months before a cycle, not at the clinic door. If you are travelling internationally, ask early whether your existing karyotype report is sufficient or whether the laboratory needs additional information or a repeat sample before probe design can begin.

    What a “normal” result means — and does not mean

    PGT-A PGT-SR
    What is examined Chromosome number across the embryo’s chromosomes Chromosome content related to the known parental rearrangement
    What “normal” suggests No aneuploidy detected in the sampled cells No unbalanced content from the rearrangement detected in the sampled cells
    What it cannot confirm That the whole embryo is normal, or that pregnancy will follow That the embryo is free of all chromosome issues, or that pregnancy will follow

    Both tests work from a biopsy sample, not the whole embryo. The regulator notes that PGT-A has limitations and can produce incorrect findings, and that a result does not guarantee a successful pregnancy or a healthy child. The same caution applies to PGT-SR: a reassuring result reduces one specific concern but does not certify the embryo.

    Mosaic findings add another layer. A mosaic PGT-A result is inferred from intermediate chromosome copy-number findings in a biopsy sample, and technical factors can contribute to such findings. A sampled result does not establish the cell composition of the whole embryo. Results and their uncertainty should be discussed with the treating clinician and a genetic counsellor.

    Practical preparation for international patients

    Before comparing quotes or booking travel, clarify these points in writing:

    • Which test is being quoted. Ask for the test name, the chromosomes it covers, and whether PGT-A and PGT-SR are being combined or offered separately.
    • Whether a parental karyotype is needed first. For PGT-SR, confirm whether your existing report is accepted and whether probe design must be completed before a cycle starts.
    • What records to gather. Karyotype reports, genetic counselling notes, previous PGT reports and any relevant family history should travel with you in dated copies.
    • Who explains the results. Confirm whether results are discussed by the treating clinician, a genetic counsellor, or both, and in what language.
    • What happens if the test is inconclusive. Ask how a failed or uninformative result would be handled and whether additional costs apply.

    Patients can and should ask licensed clinicians about diagnosis, test options, risks, reports and individual chances. A coordination service can help organise records, request appointments and compare what each quote includes, but it does not diagnose, interpret results or recommend a particular test.

    Where the two tests sit alongside PGT-M

    PGT-M addresses a known monogenic condition, PGT-SR addresses a known structural rearrangement, and PGT-A addresses chromosome number. Each answers a different question, and none is a universal requirement. Whether any of them is appropriate depends on your history, your records and a clinical assessment — not on a general claim that more testing is better.

    If you are weighing a previous IVF plan against a new proposal, it helps to compare the tests named in each plan side by side, including what each was meant to detect. A structured comparison of recommendations can make those differences visible before a consultation.

    Frequently asked questions

    Can PGT-SR also detect aneuploidy?

    PGT-SR is designed around a specific parental structural rearrangement and the chromosomes involved. Whether a clinic's PGT-SR protocol also reports general chromosome-number findings varies by laboratory and test design, so ask the treating team exactly what a given report will and will not cover rather than assuming.

    Do I need a karyotype before starting PGT-SR?

    PGT-SR depends on a documented parental rearrangement so that a tailored probe can be designed. Ask the laboratory whether your existing karyotype report is sufficient or whether additional information or a repeat sample is needed, and how long probe design takes before a cycle can begin.

  • Questions to Ask a Genetic Counsellor About Combining PGT-M and PGT-A

    PGT-M and PGT-A are not two versions of the same test. PGT-M looks for a known single-gene condition that runs in a family; PGT-A looks at chromosome number in the embryo. When a clinic plans both, the laboratory is being asked to answer two separate questions from cells taken in a single biopsy. That is why the counselling conversation matters: it is where test design, limitations and reporting responsibilities get pinned down before any cycle begins.

    You do not need to arrive with technical knowledge. You do need to arrive with the right questions and the right records. Below is a way to organise both.

    Start with what each test is actually asking

    It helps to separate the two layers before discussing how they combine. PGT-M concerns a known monogenic condition, while PGT-SR concerns chromosomal structural rearrangements — a different question again. PGT-A assesses chromosome number in cells sampled from an embryo. Each test addresses a distinct question, and a treating team and genetic counsellor should discuss the relevant family history, test design and suitability for your situation.

    If you are still sorting out which test is which, a plain-language comparison of PGT-A, PGT-M and PGT-SR is a reasonable place to start before the appointment. The goal of the counselling session is not to re-learn definitions but to apply them to your family.

    Test design: the questions that shape the whole cycle

    Test design is where most of the practical uncertainty sits when two tests are combined. Ask these directly, and ask for the answers in writing if the appointment is remote.

    • Same sample or separate biopsies? Can the laboratory perform both the PGT-M and PGT-A analysis on the same trophectoderm sample, or would a second biopsy be needed? A second biopsy is not a neutral detail — embryo biopsy can cause damage and prevent further development, so the number of sampling events is worth clarifying.
    • How is the PGT-M assay built for our family? PGT-M testing is customised to a specific known condition and family variant. Ask how the assay is designed, what validation steps precede clinical use, and how long that preparation takes relative to your intended cycle dates.
    • Are linked markers needed, and what if we are uninformative? Some PGT-M designs rely on informative genetic markers flanking the variant. Ask whether your family’s results provide enough information, and what the laboratory does if they do not — for example, whether additional family samples would be requested.
    • How does whole-genome amplification interact with the two readouts? Both analyses typically begin from amplified DNA from the same few cells. Ask how the laboratory handles the possibility that amplification or the PGT-M assay itself affects the quality of the chromosome-number readout, and whether one test is prioritised if sample quality is limited.
    • What happens to embryos that are unaffected by the PGT-M result but abnormal on PGT-A? The two results can point in different directions. Ask in advance how such embryos would be classified and discussed.

    Limitations: what neither test can promise

    This is the part patients most often wish they had asked about earlier. A combined report can look authoritative while still carrying real uncertainty at both layers.

    PGT-A has recognised limitations and can produce incorrect findings. A mosaic PGT-A result is inferred from intermediate chromosome copy-number findings in a biopsy sample; technical factors can contribute to such findings, and a sampled result does not establish the cell composition of the whole embryo. In other words, the report describes the sample, not a confirmed diagnosis of the embryo.

    PGT-M carries its own boundaries. It addresses the specific variant the assay was designed for; it is not a general screen for other genetic conditions. Either layer can return a no-result or an inconclusive call, and the laboratory may or may not be able to re-test.

    Ask your counsellor to state plainly that neither test guarantees implantation, a successful pregnancy or a healthy child, and to explain what a no-result would mean for your decision-making before you are in the position of receiving one. If you want to prepare for that scenario specifically, the questions in the guide to no-result PGT reports pair well with this conversation.

    Reporting: who explains which part, and how

    A combined report has more than one section, and it is reasonable to ask who owns each one.

    • Which clinician or counsellor explains the PGT-M interpretation, and who explains the PGT-A interpretation?
    • If the two results are discordant or one is uninformative, who coordinates the discussion and in what timeframe?
    • What confirmatory testing during a later pregnancy might be discussed, and who would arrange it?
    • Which results will be released to you directly, and in what format?

    These are not bureaucratic questions. They determine whether you receive one coherent explanation or two partial ones. A useful companion read is the discussion of who should explain PGT findings and treatment options.

    Records to gather before the appointment

    Counselling about a combined test is only as specific as the information the counsellor has. Before a remote or in-person appointment, collect:

    • The genetic test report confirming the family variant, including the gene, the specific change and the laboratory that reported it.
    • Relevant family history, including which relatives are affected and how they are related to you.
    • Reports from any previous IVF or PGT cycles, including biopsy, amplification or no-result information.
    • Names and contact details of the clinicians who ordered the original genetic testing, in case the laboratory needs to follow up.

    If you are consulting a clinic in Thailand from abroad, it also helps to confirm the appointment format, the language of the consultation, whether an interpreter is needed, and how documents should be sent. A terminology worksheet prepared for a remote consultation can reduce misunderstandings about terms such as informative, no-result and mosaic.

    A worked planning example

    Suppose a couple knows the family variant and has an appointment with a counsellor six weeks before a planned cycle. A practical preparation sequence might look like this:

    1. Send the original genetic report and family history ahead of the appointment, and ask whether any relative’s sample would be needed for marker work.
    2. Ask in writing whether both tests can run on one biopsy sample, and what the laboratory’s fallback is if sample quality is limited.
    3. Ask for a short written summary of what a no-result, an inconclusive PGT-M call or a mosaic PGT-A result would each mean for next steps.
    4. Confirm which named clinician will explain each part of the report and how results reach you.
    5. Ask what the timeline for assay preparation means for your intended dates, and keep that answer with your cycle planning notes.

    None of these steps requires you to interpret a result yourself. They simply make sure the clinical team has what it needs and that you know where each answer will come from.

    Where coordination ends and clinical advice begins

    Patients can and should ask licensed clinicians about diagnosis, options, risks, reports and their individual chances — that is exactly what the counselling appointment is for. A patient coordination service works on a different layer: organising records, requesting appointments and remote consultation formats, clarifying language needs, and helping with follow-up communication after you return home. It does not interpret genetic results, advise on test choice or predict outcomes. If you would like help assembling records and questions before approaching a clinic, you can request a case review and the scope will be confirmed with you individually.

    Frequently asked questions

    Can PGT-M and PGT-A be done on the same embryo biopsy?

    That is a laboratory design question, and the answer depends on the clinic and the assay. Ask your counsellor or treating team directly whether both analyses can run on the same trophectoderm sample, and what the plan is if sample quality is limited. A second biopsy is not a trivial step, since embryo biopsy can cause damage and prevent further development.

    If PGT-M says an embryo is unaffected, does a PGT-A result still matter?

    They answer different questions. PGT-M addresses the specific family variant, while PGT-A looks at chromosome number in the sampled cells. A combined report can therefore contain two results that point in different directions. Ask in advance how such embryos would be classified and discussed, rather than deciding in the moment.

  • Why PGT-A and PGT-M Answer Different Genetic Questions

    Two embryos can both receive a “normal” result and still be tested for completely different reasons. That is the simplest way to understand why PGT-A and PGT-M are not interchangeable: they are built to answer different questions, using different laboratory designs, and each has its own blind spots.

    PGT-A asks whether an embryo’s cells show the expected number of chromosomes. PGT-M asks whether an embryo inherited a specific genetic variant that is already known to run in a family. Neither test is a general certificate of embryo health, and neither guarantees a pregnancy or a healthy child.

    What PGT-A is designed to look at

    PGT-A stands for pre-implantation genetic testing for aneuploidy. Aneuploidy means an abnormal number of chromosomes — for example, an extra copy or a missing copy of a particular chromosome. According to the HFEA’s patient information on PGT-A, the test assesses chromosome number in cells sampled from an embryo.

    That scope matters. PGT-A is a genome-wide count, not a search for a named condition. It does not know that a particular family carries a variant in a particular gene, and it is not designed to detect one. A PGT-A report may flag an abnormal chromosome count, or it may describe a mosaic finding — an intermediate result inferred from the biopsy sample. As the ASRM committee opinion on mosaic PGT-A results explains, technical factors can contribute to such findings, and a sampled result does not establish the cell composition of the whole embryo.

    So a reassuring PGT-A result means the biopsy did not show an abnormal chromosome count. It says nothing about a single-gene condition your family may carry.

    What PGT-M is designed to look at

    PGT-M stands for pre-implantation genetic testing for monogenic disorders — conditions caused by a variant in a single gene. The HFEA’s information on PGT-M and PGT-SR describes PGT-M as testing for a known monogenic condition, and notes that a treating team and genetic counsellor should discuss the relevant history, test design and suitability.

    That word “known” carries a lot of weight. PGT-M is not a scan for unknown problems. It is a targeted test built around a specific variant — or, in some designs, around linked markers near that variant — that has already been identified through prior testing of the family or the parents. The laboratory needs that information to build a reliable assay before it can report whether an embryo inherited the variant.

    Because the test is targeted, a PGT-M result tells you about that one condition. It does not confirm that the embryo’s chromosome number is normal across the genome. A separate test would be needed for that question.

    A side-by-side view

    Question PGT-A PGT-M
    What is being examined? Chromosome number across the genome Inheritance of a known familial variant
    Does it need prior family testing? No — it is not built around a family variant Yes — the assay depends on known variant information
    Can it rule out a known single-gene condition? No It is designed to address that condition, within the limits of the assay
    Can it confirm normal chromosome number? It assesses this, with limitations No
    Typical report language Aneuploid, euploid, mosaic, no result Variant present, variant absent, inconclusive, no result

    PGT-SR is a third category, used when a parent carries a chromosomal structural rearrangement rather than a single-gene variant. It is a distinct question again, and the HFEA source above groups it with PGT-M only to distinguish their separate purposes.

    Why a normal PGT-A result does not cover a family condition

    This is the point that most often causes confusion. A couple who knows they carry a variant for a single-gene condition may assume that a “normal” PGT-A result means the embryo is unaffected. It does not. PGT-A was never looking at that gene. The variant could be present in an embryo whose chromosome count looks normal on biopsy.

    The reverse is also true. An embryo reported as unaffected on PGT-M may still have an abnormal chromosome count, because PGT-M does not assess that. Each result answers its own question and leaves the other open.

    When the two tests are combined

    Some families are advised to consider both tests together: PGT-M for the known condition and PGT-A for chromosome number. Combining them can address two separate questions in one biopsy, but it is not automatically the right choice for everyone.

    It is worth asking your clinician what the combination adds in your situation, and what it costs — in biopsy material, laboratory analysis, time and counselling. A combined approach also means two sets of results to interpret, each with its own uncertainty. The decision belongs with your treating team and genetic counsellor, who can weigh your history and the test design.

    Limits that apply to both tests

    • Sampling, not the whole embryo. Both tests work from a small biopsy. A result describes the sample, and the ASRM opinion stresses that a sampled result does not establish the whole embryo’s cell composition.
    • Mosaicism. Intermediate PGT-A findings can be technically influenced and need careful discussion rather than a simple label.
    • No-result or inconclusive outcomes. Some biopsies do not yield a clear answer, and a repeat may or may not be possible.
    • Variants of uncertain significance. A variant’s link to disease is not always clear, which can complicate PGT-M design.
    • Residual risk. Neither test removes all uncertainty about an embryo or a pregnancy.
    • Biopsy itself carries a risk. The HFEA’s PGT-A questions and answers note that embryo biopsy can cause damage and prevent further development.

    Neither test guarantees a successful pregnancy or a healthy child, and neither is a required step for every patient. Whether testing is appropriate is an individual clinical decision.

    Preparing for a useful conversation about test design

    You can ask your clinician or genetic counsellor directly about diagnosis, options, risks, reports and your individual chances. A few preparation points help that conversation stay concrete:

    • Bring any prior genetic reports — the family variant, who was tested, and what the laboratory found.
    • Ask which test is being proposed and exactly what question it answers.
    • Ask what the report will and will not tell you, including how no-result and mosaic findings are handled.
    • Ask whether a combined approach is being considered and why.
    • Keep a dated record of what was discussed and what remains open.

    If you are comparing clinics or gathering information before a consultation, our guide to PGT-A, PGT-M and PGT-SR differences for international patients sets out the categories in more detail, and how to read PGT-A results covers report language. For families weighing a known condition, PGT-M versus PGT-A for single gene disorders goes further into that comparison.

    Coordination support can help with the practical side: organising records and prior genetic reports, requesting a remote consultation, planning travel around confirmed appointments, and arranging a records handover before you return home. Clinicians interpret results and make treatment decisions; the coordinating service does not diagnose or prescribe.

    Frequently asked questions

    If I have PGT-A done, do I still need PGT-M for a known family condition?

    They answer different questions. PGT-A assesses chromosome number and is not designed to detect a specific single-gene variant, so a normal PGT-A result does not rule out a known familial condition. Whether PGT-M is appropriate for you is a clinical decision for your treating team and genetic counsellor.

    Can PGT-M tell me whether an embryo's chromosomes are normal?

    No. PGT-M is targeted at a known variant and does not confirm chromosome number across the genome. If both questions matter in your situation, ask your clinician whether a combined approach is being considered and what it involves.

  • Piezo-ICSI vs Conventional ICSI: What the Difference Means for Your Treatment Plan

    ICSI, or intracytoplasmic sperm injection, is a laboratory step in which an embryologist picks up a single sperm and injects it into a mature egg. Piezo-ICSI is a variation on that step. The difference is not in what the procedure is trying to achieve, but in how the injection needle enters the egg.

    In conventional ICSI, the embryologist advances the injection pipette through the egg’s outer layers and membrane using manual control, often with a hydraulic or air-driven system. In Piezo-ICSI, the pipette is driven by a piezoelectric element that produces very fine, controlled vibrations. The needle tip is brought to the egg membrane and a small, precise movement is used to breach it, rather than pushing through in one continuous advance.

    That is the core mechanical distinction. Everything else — why a clinic might offer it, whether it changes your chances, and how it fits with genetic testing — follows from that difference and from the evidence available for it.

    What actually changes at the microscope

    During conventional ICSI, the embryologist must break the egg membrane to deliver the sperm. This is a delicate moment: the membrane can dimple and resist before it gives way, and the release of pressure can disturb the egg’s internal structure. The skill of the embryologist matters a great deal here.

    With Piezo-ICSI, the vibration is used to make a small opening at the point of contact. The idea is that less force and less deformation are applied to the egg. Proponents describe this as a gentler penetration step. It is a plausible mechanical rationale, and it is the reason the technique is discussed at all.

    What this article cannot tell you is how much that gentleness matters in your case. That depends on the eggs, the sperm, the laboratory, and the clinical history — questions for the treating team, not for a general guide.

    Why egg survival and fertilization are the focus

    The outcome most closely tied to the injection step is whether the egg survives the procedure and whether fertilization follows. Eggs vary in how robust their membranes are, and some are more fragile than others. In situations where a clinic is concerned about egg fragility or about fertilization results in a previous cycle, the way the needle enters the egg becomes a more relevant variable.

    This is where the discussion of indications usually begins. A clinic might consider Piezo-ICSI when there is a history of poor fertilization after conventional ICSI, when few eggs are available, or when the treating embryologist judges the eggs to be delicate. These are clinical judgements made with the full picture of your cycle, not rules that can be applied from a website.

    It is worth being clear about the limits of the evidence. The mechanical description of Piezo-ICSI is well established. Whether it improves live birth rates compared with conventional ICSI is a separate question, and one that should be answered by your clinic with reference to the evidence it relies on. Ask directly: what does the evidence show, and how does it apply to my situation?

    Indications: who a clinic might consider it for

    There is no universal list of indications that applies to every patient or every laboratory. The following are the kinds of situations in which the question tends to come up, and they should be discussed with a licensed clinician who can review your history:

    • Previous poor fertilization after a conventional ICSI cycle, where the team wants to examine whether the injection technique contributed.
    • Fragile or limited eggs, where the embryologist judges that a gentler penetration step may be preferable.
    • Small numbers of mature eggs, where each egg carries more weight in the cycle.
    • Laboratory preference or protocol, where a clinic uses Piezo-ICSI as its standard or offers it as an option for selected cases.

    None of these is a guarantee that Piezo-ICSI will be used, or that it will change an outcome. They are conversation starters. The decision belongs with the treating clinician and embryology team, who can see the eggs and the laboratory conditions in front of them.

    What to verify about a Thai laboratory

    If Piezo-ICSI matters to your planning, the first thing to establish is whether the laboratory you are considering actually offers it. Not every IVF laboratory has a piezo-driven injection system, and availability can differ between clinics and even between locations of the same group.

    Useful questions to put in writing before you commit to a cycle:

    • Does this laboratory perform Piezo-ICSI, and is the equipment on site?
    • Is it offered routinely, only for selected cases, or not at all?
    • Who decides whether it is used — the treating doctor, the embryologist, or both — and when in the cycle is that decision made?
    • If it is used, is there an additional charge, and is that charge included in the quoted package or billed separately?
    • What does the clinic’s own evidence and experience suggest about when it is appropriate?

    These are factual questions about services and billing. They are reasonable to ask before treatment, and the answers should be confirmed in writing rather than assumed from a website or a conversation.

    How this interacts with PGT planning

    If you are planning preimplantation genetic testing, the ICSI decision sits upstream of the testing. PGT-A assesses chromosome number in cells sampled from an embryo, and the biopsy happens later in the laboratory process. The way fertilization was achieved does not change what PGT-A is measuring, but it does affect how many embryos reach the biopsy stage.

    That is the practical link. A cycle that produces few fertilized eggs gives the laboratory less to work with, and the testing pathway has fewer embryos to assess. This is one reason the injection technique can feel consequential when embryo numbers are expected to be low. It is also why the conversation about Piezo-ICSI belongs with the conversation about whether PGT is appropriate for you at all.

    PGT-A has limitations. The HFEA notes that testing can produce incorrect findings and does not guarantee a successful pregnancy or a healthy child. A biopsy can also damage an embryo and prevent further development. These are reasons to discuss the testing decision carefully with your clinician and a genetic counsellor, not reasons to avoid the conversation.

    A practical way to organise the decision

    Rather than treating Piezo-ICSI as a standalone choice, place it in the sequence of decisions for your cycle:

    1. Clarify the fertilization plan. Ask whether conventional ICSI, Piezo-ICSI, or another approach is proposed, and why. The guide to choosing between IVF and ICSI is a useful starting point for the wider decision.
    2. Confirm laboratory capability and cost. Establish whether the technique is available, how it is selected, and whether it appears in the quotation. The article on what a typical IVF package in Thailand includes can help you read a quote critically.
    3. Connect it to the PGT decision. If testing is planned, ask how the fertilization approach affects the number of embryos likely to reach biopsy, and what happens if too few do.
    4. Record the answers. Keep dated notes of what was confirmed, by whom, and what remains open. This is especially useful if you are coordinating between a home clinic and a Thai hospital.

    If you are arranging a remote consultation, it helps to send your history and your specific questions in advance so the clinician can address the fertilization plan and the testing plan together. Coordination support can help organise those questions and the records that go with them; the clinical judgement stays with the treating team.

    Where the coordinator’s role ends

    Thailand PGT can help you prepare questions, organise records, coordinate appointment and remote-consultation requests, assist with travel and language needs around confirmed appointments, and help request records for follow-up after you return home. We do not diagnose, prescribe, interpret results, or decide which fertilization technique is right for you. Those decisions rest with licensed clinicians who can review your individual history.

    The most useful thing you can do at the research stage is to separate what is known from what needs confirming. The mechanical difference between Piezo-ICSI and conventional ICSI is clear. Whether it is available where you plan to treat, whether it is indicated for you, and what it costs are questions with specific answers that only the clinic can give — and they are worth asking before the cycle begins, not after.

    Frequently asked questions

    Is Piezo-ICSI always better than conventional ICSI?

    No. The two techniques differ in how the injection needle enters the egg, and Piezo-ICSI is described as a gentler penetration step. Whether that matters for a particular patient depends on the eggs, the laboratory, and the clinical history. Ask your treating clinician what the evidence shows for your situation rather than assuming one technique is superior.

    Does using Piezo-ICSI change what PGT-A measures?

    No. PGT-A assesses chromosome number in cells sampled from an embryo, and the biopsy happens after fertilization. The fertilization technique affects how many embryos may reach the biopsy stage, but it does not change what the test is measuring or its limitations.

  • Sperm DNA Fragmentation Testing at an Older Paternal Age: What to Ask

    Sperm DNA fragmentation testing is often raised when a couple is planning IVF and the father is older. The useful question is not simply whether the test exists or what it costs, but whether it is indicated in your situation, what the number actually measures, and what you and your clinician would do differently depending on the result. A test that does not change a decision is worth questioning before you pay for it.

    This guide sets out the questions worth bringing to a consultation, in roughly the order they tend to matter. It does not tell you whether you need the test. That is an individual clinical judgement, and it belongs with a licensed clinician who has your history, semen analysis and treatment record.

    Start with the indication, not the test

    Age alone is a weak reason to order a test. Paternal age is relevant to fertility planning, but a clinician is likely to weigh it alongside other findings rather than treat a birthday as a stand-alone indication. Ask directly: In my case, what specifically makes sperm DNA fragmentation testing worth considering, and what would make you skip it?

    Triggers that are commonly discussed in this context include:

    • Recurrent pregnancy loss where no other explanation has been found
    • Repeated IVF cycles with poor fertilisation, poor embryo development or repeated implantation failure
    • Abnormal semen parameters on one or more analyses
    • A clinical varicocele or other male-factor diagnosis under evaluation
    • Planning a treatment step where sperm selection method is genuinely open to choice

    These are conversation starters, not a checklist that decides anything. The point of asking is to hear your clinician’s reasoning, including the possibility that the answer is “not indicated yet”. A clear “no, and here is why” is a useful answer.

    What the test measures, and what it does not

    Sperm DNA fragmentation testing estimates the proportion of sperm with damaged or broken DNA strands. It is a separate measurement from sperm count, motility and morphology, and it is separate again from the chromosomal status of an embryo.

    Two misunderstandings are worth clearing up early:

    • It is not an aneuploidy test. A fragmentation result does not tell you whether an embryo has the wrong number of chromosomes, and it does not replace preimplantation genetic testing for aneuploidy (PGT-A) if that is being considered for separate reasons.
    • It is not a fertility score. A result does not predict whether a given couple will or will not have a baby, and it should not be presented to you as one.

    If PGT-A is already part of your planning, the two discussions can sit side by side without one substituting for the other. The article on PGT-A and advanced paternal age covers that separate decision.

    Ask how the test is done and how the cut-off was set

    Laboratory method matters more than many patients expect. The UK fertility regulator, the HFEA, notes that sperm DNA fragmentation test methods and their interpretation are not standardised. That has a practical consequence: a number from one laboratory is not automatically comparable with a number from another, and a single threshold does not mean the same thing everywhere.

    Useful questions include:

    • Which assay does your laboratory use, and what is its own reference range?
    • Is the result reported as a percentage with a stated cut-off, and how was that cut-off established?
    • How much does a result near the threshold vary between samples from the same person?
    • If the first result is borderline or high, would you repeat it before acting on it, and after how long?

    You are not looking for a single “correct” number. You are checking whether your clinician treats the result as a stable measurement or as one imperfect data point among several.

    What a high result could actually change

    This is the question that decides whether the test earns its place in your plan. Ask your clinician to walk through the realistic options if the result comes back high, and to say plainly which of them have good supporting evidence and which do not.

    Areas that are commonly discussed include:

    • General health and lifestyle review — for example smoking, heat exposure, sleep, weight and other modifiable factors, discussed with your clinician rather than self-prescribed.
    • Antioxidant or other supplements — ask whether there is evidence that a particular supplement changes outcomes that matter to you, and whether any interaction with your other medication is a concern.
    • Sperm selection techniques — for example magnetic-activated cell sorting (MACS), which the HFEA describes as using magnetic sorting to separate sperm by surface signals associated with damaged or dying cells. The same HFEA guidance assesses sperm selection following sperm DNA fragmentation testing, including MACS, as having insufficient moderate- or high-quality evidence for improving the chance of having a baby in male-factor infertility. Ask your clinic how it presents this, and whether it would charge extra for it.
    • Surgical sperm retrieval — sometimes raised where fragmentation is high and other options are limited; ask about the evidence, the risks and whether it fits your situation.
    • Timing and technique of ICSI — ask whether the result would change how or when the laboratory handles the sample.
    • Whether PGT-A remains relevant — a fragmentation result does not answer the aneuploidy question, so ask how the two decisions interact in your plan.

    If none of these would change for you, that is important information. It may mean the test adds cost and anxiety without altering the plan.

    Ask who interprets the report, and get a copy

    A result without interpretation is easy to misread, especially when the assay and cut-off are unfamiliar. Before testing, confirm:

    • Who will explain the result to you, and in what format — a scheduled consultation, a written summary, or both?
    • Will the laboratory report be released to you, and in what language?
    • If you are consulting remotely from abroad, how will the result discussion be arranged and at what cost?
    • Who holds the report if you continue treatment elsewhere, and how would it be transferred with your consent?

    If you are gathering records before a first consultation, the guide to male fertility testing for international couples explains what tends to be useful to bring. For the practical side of sample and partner preparation, see the PGT IVF partner and sperm requirements checklist.

    Practical coordination questions

    Once the clinical questions are settled, the logistics are straightforward but worth confirming in writing:

    • What is the total cost of the test, including any repeat sample, consultation to discuss the result, and any add-on sperm selection?
    • What is the turnaround time, and does it fit your treatment dates or travel window?
    • Can the sample be produced locally and shipped, or does it need to be given at the clinic?
    • If you are travelling to Thailand, does the result need to be available before a treatment decision, or can planning proceed in parallel?

    Coordination support can help organise these questions, request the report and arrange a remote consultation, but the interpretation and any treatment recommendation come from your clinician. If you would like help preparing a question list and comparing what different clinics include, you can request a case review.

    A worked planning example

    Consider a couple where the father is in his late forties, there has been one miscarriage, and the semen analysis is within normal limits. Rather than booking the test immediately, they ask three questions at consultation: what in our history suggests fragmentation is contributing; what would we do differently if the result were high; and would we repeat a borderline result before acting on it. The clinician explains that with a single miscarriage and normal parameters, the test is unlikely to change the plan, and that if a high result appeared, the main discussion would be about sperm selection with limited supporting evidence and about general health factors. The couple decide to defer the test and revisit it only if further cycles fail. That is a legitimate outcome of asking.

    In another situation — repeated failed cycles with no clear explanation — the same questions may lead to testing, a repeat if borderline, and a documented discussion of what would change. The difference is the indication, not the age.

    What to leave the consultation with

    • A plain statement of why the test is or is not indicated for you
    • The assay, reference range and repeat policy in writing
    • A list of what would change if the result were high, with the strength of evidence noted
    • The name of the clinician who will interpret the result and how you will receive it
    • Costs, turnaround and record-transfer arrangements confirmed

    Older paternal age is a reasonable prompt to ask questions. It is not, by itself, an answer about whether this particular test belongs in your care.

    Frequently asked questions

    Does older paternal age on its own mean I should have sperm DNA fragmentation testing?

    Not automatically. Age is one factor a clinician may weigh alongside your history, semen analysis results and any previous cycles. Ask what specifically in your case makes the test worth considering, and what would make your clinician skip it.

    If my sperm DNA fragmentation result is high, does that mean we need PGT-A?

    No. Fragmentation testing looks at DNA damage in sperm, while PGT-A looks at the chromosomal status of an embryo. They answer different questions, and a fragmentation result neither requires nor replaces PGT-A. Ask your clinician how each decision fits your plan.

  • PGT-A: What It Tests, What It Cannot Tell You, and Where the Limits Lie

    The short answer

    PGT-A looks at the number of chromosomes in a small sample of cells taken from an embryo. It is designed to flag embryos with an extra or missing chromosome, a pattern called aneuploidy. It does not read the genetic code letter by letter, and it does not confirm that an embryo will implant, grow normally or lead to a healthy child. The HFEA’s patient information on PGT-A describes it as an assessment of chromosome number in sampled embryo cells, with limitations and the possibility of incorrect findings.

    That distinction matters when you are deciding whether testing belongs in your treatment plan. PGT-A is a screening tool that adds information to a decision, not a verdict on an embryo’s future.

    What the test actually examines

    Human cells normally carry 46 chromosomes in 23 pairs. In aneuploidy, there is a whole extra chromosome or one missing, or a larger departure from the usual number. PGT-A is built to detect that kind of copy-number difference.

    The sample usually comes from the trophectoderm, the outer cell layer of a blastocyst-stage embryo, taken by biopsy. Only a handful of cells are removed, while the rest of the embryo continues in the laboratory. The result you receive describes those sampled cells.

    What PGT-A is not looking for

    PGT-A does not sequence individual genes, so it is not a test for a specific inherited condition running in a family. Those questions belong to PGT-M, which addresses a known monogenic condition, and PGT-SR, which addresses chromosomal structural rearrangements. The HFEA’s overview of PGT-M and PGT-SR makes clear that these tests answer different questions and require discussion of the relevant history and test design with a treating team and genetic counsellor.

    If your reason for testing is a known family condition or a known rearrangement, say so early. The test you need may not be PGT-A at all, and the laboratory preparation can differ.

    Where the limitations sit

    A sample is not the whole embryo

    The biopsy describes a few cells. It cannot establish the cell composition of the entire embryo. This is the core reason a PGT-A report is best read as a sample-based finding rather than a whole-embryo diagnosis.

    Mosaic results and their uncertain meaning

    Sometimes a report shows an intermediate chromosome copy-number pattern rather than a clear normal or clear abnormal result. This is often described as mosaicism. The ASRM committee opinion on mosaic PGT-A results notes that such a result is inferred from intermediate findings in a biopsy sample, that technical factors can contribute, and that the sampled result does not establish the composition of the whole embryo. It recommends discussing the result and its uncertainty with the treating clinician and a genetic counsellor.

    In practice, a mosaic report is one of the situations where patients most need a conversation rather than a search engine. What the finding means for a particular embryo, and how it should be weighed, is a clinical judgement that depends on the full report and your history.

    Technical accuracy and sampling error

    No laboratory test is perfect. The HFEA notes that PGT-A can produce incorrect findings, and that whether to use it should be discussed for the individual situation. A result can be affected by the biopsy itself and by the limits of the platform used. This is why the laboratory’s methods, validation and reporting language are fair questions to put to your treating team.

    Biopsy carries its own small risk

    Removing cells is a procedure on the embryo. The HFEA’s PGT-A questions and answers state that embryo biopsy can cause damage and prevent further development. It does not publish a figure that can be transferred to any particular clinic or laboratory, so treat any single percentage you see quoted online with caution and ask what your own clinic’s experience and consent discussion cover.

    A normal result is not an outcome

    An embryo reported as having the expected chromosome number may still fail to implant, and a pregnancy may still face its own uncertainties. PGT-A does not measure embryo appearance or grading, does not assess the receptivity of the uterine lining, and does not remove the influence of maternal age on an individual cycle. It also cannot promise a successful pregnancy or a healthy child, as the HFEA’s PGT-A information states.

    Testing can leave you with fewer embryos to transfer

    Because embryos with an abnormal result are usually not selected for transfer, testing can reduce the number available. If few embryos reach the biopsy stage, it is possible to finish a cycle with no embryo reported as suitable for transfer. That possibility belongs in the decision before testing, not after the report arrives. It is also why the number of embryos you are likely to have matters when discussing individual suitability.

    Individual suitability is a clinical discussion, not a rule

    There is no universal checklist that decides who should have PGT-A. The HFEA frames the decision as one to discuss for the individual situation. In a consultation, the conversation commonly touches on:

    • your age at the time of treatment and what that means for chromosome risk in embryos
    • ovarian reserve and how many eggs and embryos a cycle may realistically produce
    • previous pregnancy losses or previous aneuploid findings
    • whether a known family condition or rearrangement points to PGT-M or PGT-SR instead
    • what you would do differently depending on the result, including whether you would consider transferring a mosaic embryo

    These are questions for a licensed clinician who can see your records. A coordination service can help you prepare and organise the conversation, but it does not diagnose, interpret your report or recommend a treatment path.

    Reading your own report

    Reports vary in wording and structure. When you go through yours, it helps to identify which of these you are looking at:

    Report wording What it generally refers to What to clarify
    Euploid or normal chromosome number No aneuploidy detected in the sampled cells That this is a sample-based finding, not a guarantee of pregnancy
    Aneuploid A chromosome copy-number difference detected in the sample Which chromosome, and how the clinic applies the result
    Mosaic An intermediate copy-number pattern in the sample What the uncertainty means for this embryo and your options
    No result or inconclusive The sample did not give a usable finding Whether a repeat biopsy is possible or advisable

    Ask your clinician to walk through the specific line relating to your embryo rather than a general explanation of the test. For a closer look at how to read a report, see how to interpret PGT-A results, and for the meaning of a normal finding, what a normal PGT result does and does not mean.

    Questions worth taking to your consultation

    You are entitled to ask your treating clinician about your diagnosis, your options, the risks, your reports and your individual chances. A short prepared list keeps the appointment focused:

    • Which test are we discussing, and why that one rather than PGT-M or PGT-SR?
    • How does the laboratory validate and report its PGT-A findings, including mosaic results?
    • What is the plan if no embryo is reported as suitable for transfer?
    • How would a mosaic result be handled in our decision-making?
    • What does the biopsy consent cover, and what is known about this laboratory’s experience?

    If you are comparing hospitals or preparing for a remote consultation, a structured question list helps you compare like with like. The Thailand PGT consultation checklist is a practical starting point, and understanding PGT-A accuracy covers what to ask about laboratory methods. If age is part of your question, PGT-A for women over 40 sets out the considerations in more detail.

    What this means for your planning

    PGT-A can add useful information about chromosome number in an embryo, and it can also narrow your options, produce uncertain results and require careful interpretation. The sensible next step is not to decide from a web page but to arrive at your consultation with your records, your questions and a clear sense of what you would do with each kind of result. If you would like help organising records, preparing questions or coordinating a remote consultation, you can request a case review; clinical interpretation and treatment decisions stay with your treating team.

    Frequently asked questions

    Does a normal PGT-A result mean the embryo is healthy?

    No. A normal result means no aneuploidy was detected in the sampled cells. It does not confirm that the embryo will implant, that the pregnancy will progress, or that the child will be healthy. Those outcomes depend on many factors the test does not examine.

    Can PGT-A tell me whether I have a family genetic condition?

    Not usually. PGT-A looks at chromosome number, not at the sequence of an individual gene. A known monogenic condition is addressed through PGT-M, and a known chromosomal structural rearrangement through PGT-SR, after discussion with your treating team and a genetic counsellor.

  • AI Embryo Scoring and the Embryologist’s Assessment: How to Read Them Together

    If your clinic mentions an AI score for your embryos, the natural question is whether it is more accurate than the person looking down the microscope. The short answer is that the two are not competing answers to the same question. An embryologist’s assessment describes what can be seen in the embryo’s structure and development. An AI score is usually a computer-generated number that ranks or estimates the likelihood of something, based on images it was trained on. Neither one is a diagnosis of the embryo, and neither guarantees a pregnancy.

    This guide explains what each output represents, where uncertainty enters, what clinical evidence can and cannot currently show, and how to keep both pieces of information in view when you discuss embryo selection with your treating clinician.

    Two different outputs, not two opinions on the same thing

    Embryologists grade embryos using established morphological criteria: how the cells divide, how compact the cell mass looks, how expanded the cavity is, and similar visible features. This is a descriptive judgement made by a trained person, and it is usually recorded in a structured format so that it can be compared over time and between colleagues.

    An AI system, by contrast, typically takes embryo images or time-lapse sequences and produces a score, a rank order, or a probability estimate. The output depends entirely on what the model was built to predict and on the data it learned from. A model trained to rank embryos by implantation potential is answering a different question from one trained to predict blastocyst formation, and the two numbers are not interchangeable.

    That is why reading an AI score “alongside” a grade means asking what each one is actually telling you, rather than treating the higher number as the better embryo.

    What an AI score usually represents

    In most clinical settings, an AI output is best understood as a decision-support signal. It may:

    • rank several embryos from the same cycle relative to each other;
    • estimate a probability of reaching a developmental milestone or of implantation;
    • flag images that look unusual compared with the training set.

    None of these is a statement about the chromosomal makeup of the embryo. Morphology and genetic testing answer separate questions, and an image-based score does not substitute for a PGT result. If you are trying to understand how appearance and genetic testing can diverge, the explanation in embryo appearance versus genetic test results is a useful companion to this article.

    Why the embryologist’s assessment still matters

    An AI model sees only what it was given: images, frames, and the variables in its input. It does not know your age, your history, the stimulation protocol, or how the laboratory handled the sample that day. The embryologist does, and can weigh the score against the whole picture, including features the model was never trained to notice.

    There is also a practical safeguard in having a human in the loop. A score that looks implausible, or an image of poor technical quality, can be recognised and set aside. The laboratory’s own procedures for how embryos are graded and selected are described in the embryologist’s role in Thai IVF clinics, which is worth reading if you want to understand who does what inside the lab.

    Where the uncertainty comes from

    Uncertainty around AI embryo scoring is not a reason to dismiss it, but it is a reason to ask precise questions. The main sources are:

    • Training data. A model learns patterns from the embryos and outcomes in its development dataset. If that population differs from you or from the clinic using it, the score’s meaning may shift.
    • Validation. Performance reported in one study does not automatically transfer to another clinic, another camera system, or another patient group.
    • Laboratory calibration. Image quality, culture conditions and grading conventions vary between labs, and a model may need local adjustment before its output is meaningful.
    • No universal standard. There is no single agreed scale for AI embryo scores, so a “0.8” from one system cannot be compared with a “0.8” from another.

    This is the same kind of caution that applies to any test used in embryo selection. Regulators note that PGT-A itself has limitations and can produce incorrect findings, and that a result does not guarantee a successful pregnancy or a healthy child (HFEA). An AI score deserves at least the same scrutiny.

    What the clinical evidence can and cannot show

    Published research on AI in embryo selection is growing, but it is uneven. Studies often differ in what they predict, how they define success, and whether they compare the AI-assisted decision with what an experienced embryologist would have chosen anyway. A model that agrees closely with embryologists may be reassuring about consistency, but it does not by itself prove that using the score improves outcomes.

    What the evidence generally does not yet establish is a universal claim that AI scoring is superior to morphological assessment for every patient, in every laboratory. Treat any clinic statement that presents AI as clearly better as something to examine: ask what it is compared with, in which population, and whether the clinic has its own data.

    Reading a score and a grade together

    A practical way to hold both in view is to ask three questions about any embryo under discussion:

    1. What does the grade describe? Ask for the morphological grade in the laboratory’s own format, and what each element means.
    2. What does the score predict? Ask what outcome the model was trained on, and whether the number is a rank within your cycle or an absolute probability.
    3. How were they combined? Ask whether the score changed the ranking, confirmed it, or was noted but not used.

    If the answers are vague, that is useful information in itself. A laboratory that can explain its own process is easier to work with than one that cannot.

    Keeping a record you can discuss later

    Embryo decisions are often made quickly, and the details are easy to lose. Before or during your cycle, ask whether you can receive the written morphological grading for each embryo, and, if an AI system is used, whether any AI report or score summary is available. Keep these with your other cycle records so that a later conversation, whether in Thailand or after you return home, starts from the same information.

    If you are preparing questions for a consultation, questions about embryo quality covers the ground in more detail, and comparing embryo grading explanations between laboratories helps if you are weighing more than one clinic’s approach.

    Who answers which question

    Questions about what a score means for your own embryos, whether it should influence the transfer decision, and what the realistic chances are belong with your treating clinician and the embryology team. They can interpret the report in the context of your history. Coordination support, by contrast, covers the practical side: organising your records, requesting written grading or score summaries, arranging a remote consultation, and passing follow-up questions to the hospital. It does not interpret results or recommend a transfer decision.

    If you are at the stage of gathering information before choosing where to be treated, a structured comparison of quotation inclusions and laboratory explanations is more useful than a ranking alone. The countrywide overview at researching IVF hospitals and clinics in Thailand is a neutral starting point for that comparison, not evidence that any provider produces better embryos or outcomes.

    A short worked example

    Suppose a cycle produces four blastocysts. The embryologist grades them, and the laboratory’s AI tool ranks them in a slightly different order. Rather than assuming the AI order is correct, you could ask: which embryo would have been chosen on morphology alone, which on the score, and why the team settled on the one it did. You could also ask whether the score was validated in this laboratory and what outcome it was trained to predict. Those three questions usually reveal whether the AI output is genuinely informing decisions or simply displayed alongside them.

    The bottom line

    An AI embryo score is a computer-generated estimate shaped by its training data and the laboratory using it. An embryologist’s assessment is a trained human description of visible embryo features. They can complement each other, but neither is a diagnosis, and neither guarantees an outcome. Read them together by asking what each one predicts, how they were combined, and what evidence supports the tool in that specific laboratory.

    Frequently asked questions

    Does a higher AI embryo score mean a better chance of pregnancy?

    Not necessarily. An AI score is usually a ranking or probability estimate based on patterns in its training data, and it does not establish an individual embryo's chromosomal makeup or guarantee an outcome. Ask your treating clinician what the score was trained to predict and how it was used in your cycle.

    Can I ask for the AI report and the embryologist's grading in writing?

    You can ask the laboratory or your treating team whether written morphological grading and any AI score summary are available for your embryos. Keeping these with your cycle records makes later discussions easier, including after you return home.